KRYS - NASDAQ

Krystal Biotech, Inc.

KRYS·NASDAQ

$301.82

+0.74%

HealthcareBiotechnology

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$8.90B

EPS7.0800

P/E Ratio42.63

Earnings Date08/03/2026

1.33B

Assets

26%

3Y+139.0%

5Y+329.0%

10Y+61027.0%

114.23M

Total Liabilities

3Y+215.0%

5Y+509.0%

10Y+5935.0%

1.22B

Total Equity

29%

3Y+134.0%

5Y+318.0%

10Y+421893.0%

Krystal Biotech, Inc. Funding & Solvency Profile

KRYS · NASDAQ

Current Assets

Cash & Cash Equivalents496.30M

Net Receivables127.42M

Inventory40.48M

Other Current Assets28.91M

Total Current Assets1 B

Non-Current Assets

Property, Plant & Equipment158.01M

Goodwill & Intangible Assets0.00

Long-Term Investments128.07M

Other Non-Current Assets287.00K

Total Non-Current Assets286 M

Total Assets

1.33B

Financial Health Analysis

Current Ratio

9.95x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.09x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

922 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

77% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Krystal Biotech, Inc. Balance Sheet

KRYS • NASDAQ

Krystal Biotech, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	496.3M	344.9M	358.3M	161.9M	341.2M	268.3M	187.5M	103.7M	49.6M	1.9M
Short-Term Investments	331.5M	252.7M	173.9M	217.3M	96.9M	3M	6.2M	8.1M	0.0	0.0
Cash & Short-Term Investments	827.8M	597.5M	532.2M	379.2M	438.1M	271.3M	193.7M	111.8M	49.6M	1.9M
Net Receivables	127.4M	104.7M	42M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	127.4M	104.7M	42M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	40.5M	26.5M	7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	4.2M	3.8M	2.2M	889K	323K	246K
Other Current Assets	28.9M	13.3M	6.7M	4.6M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	1B	742M	587.9M	383.8M	442.3M	275.1M	195.9M	112.7M	49.9M	2.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	158M	161.4M	168.2M	169.7M	119.6M	34.2M	11.2M	3M	200K	13K
Long-Term Investments	128.1M	152.1M	62M	4.6M	64.4M	0.0	497K	0.0	0.0	0.0
Tax Assets	22.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	287K	231K	263K	324K	74K	1.6M	1.5M	452K	0.0	0.0
Total Non-Current Assets	309.2M	313.8M	230.4M	174.7M	184M	35.8M	13.1M	3.5M	200K	13K
Total Assets	1.3B	1.1B	818.4M	558.5M	626.3M	310.8M	209M	116.1M	50.1M	2.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.2M	9.3M	6.1M	4M	8.5M	2.1M	1.1M	888K	193K	42K
Accounts Payable	3.2M	5M	1.8M	4M	8.4M	2.1M	1M	888K	193K	42K
Other Payables	0.0	4.3M	4.2M	43K	83K	40K	40K	0.0	0.0	0.0
Accrued Expenses	0.0	89.1M	8.8M	23M	16.1M	5M	1.8M	348K	10K	1K
Capital Lease Obligations (Current)	1.8M	1.2M	1.5M	1.6M	1M	8.2M	480K	0.0	0.0	0.0
Tax Payables	0.0	4.3M	2.3M	43K	83K	40K	40K	154K	103K	0.0
Other Current Liabilities	97.9M	2.4M	16.8M	267K	87K	26K	12K	1.4M	437K	0.0
Total Current Liabilities	102.9M	102M	33.1M	28.8M	25.7M	15.5M	3.3M	2.6M	640K	43K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8M
Other Non-Current Liabilities	3.7M	1.4M	0.0	0.0	0.0	0.0	0.0	294K	0.0	7K
Total Non-Current Liabilities	11.3M	7.5M	6.6M	7.4M	7M	3.3M	2.8M	294K	0.0	1.9M
Capital Lease Obligations	9.3M	7.3M	8.1M	8.9M	8M	11.5M	3.3M	0.0	0.0	0.0
Total Liabilities	114.2M	109.5M	39.7M	36.2M	32.7M	18.8M	6.1M	2.9M	640K	1.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50.1M	1.4M
Additional Paid-In Capital	1.2B	1.1B	1B	803.7M	734.5M	363.3M	242M	133.2M	58.5M	33K
Retained Earnings	24.2M	-180.7M	-269.8M	-280.8M	-140.8M	-71.2M	-39M	-20M	-9.1M	-1.2M
Accumulated Other Comprehensive Income/Loss	1.1M	-190K	638K	-728K	-163K	6K	10K	2K	-25K	-2K
Total Stockholders' Equity	1.2B	946.4M	778.6M	522.2M	593.6M	292.1M	202.9M	113.2M	49.5M	289K
Total Equity	1.2B	946.4M	778.6M	522.2M	593.6M	292.1M	202.9M	113.2M	49.5M	289K
SUMMARY
Total Liabilities & Equity	1.3B	1.1B	818.4M	558.5M	626.3M	310.8M	209M	116.1M	50.1M	2.2M
Total Investments	459.6M	404.8M	235.8M	221.9M	161.2M	3M	6.7M	8.1M	0.0	0.0
Total Debt	9.3M	7.3M	8.1M	8.9M	8M	11.5M	3.3M	0.0	0.0	1.8M
Net Debt	-487M	-337.6M	-350.2M	-153M	-333.2M	-256.7M	-184.3M	-103.7M	-49.6M	-80K
Shares Outstanding	28,942,981	28,942,981	28,942,981	28,942,981	28,942,981	28,942,981	28,942,981	28,942,981	28,942,981	28,942,981

SEC Filings

KRYS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 20, 2026	May 15, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 03, 2026	April 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 23, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing

Showing 1 to 10 of 157 filings

Related Guides

Blog Categories

Continue your KRYS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.